Skip to main content Back to Top
Advertisement

7/15/2021

Chlordiazepoxide Capsules

Products Affected - Description

    • Chlordiazepoxide capsule, Mylan Institutional, 10 mg, unit-dose blister pack, 100 count, NDC 51079-0375-20 - discontinued
    • Chlordiazepoxide capsule, Mylan Institutional, 25 mg, unit-dose blister pack, 100 count, NDC 51079-0141-20 - discontinued
    • Chlordiazepoxide capsule, Mylan Institutional, 5 mg, unit-dose blister pack, 100 count, NDC 51079-0374-20 - discontinued
    • Chlordiazepoxide capsule, Teva, 10 mg, bottle, 100 count, NDC 00555-0033-02
    • Chlordiazepoxide capsule, Teva, 10 mg, bottle, 500 count, NDC 00555-0033-05
    • Chlordiazepoxide capsule, Teva, 25 mg, bottle, 100 count, NDC 00555-0159-02
    • Chlordiazepoxide capsule, Teva, 25 mg, bottle, 500 count, NDC 00555-0159-04
    • Chlordiazepoxide capsule, Teva, 5 mg, bottle, 100 count, NDC 00555-0158-02
    • Chlordiazepoxide capsule, Teva, 5 mg, bottle, 500 count, NDC 00555-0158-04

Reason for the Shortage

    • Mylan discontinued chlordiazepoxide capsules in early-2021.
    • Teva did not provide a reason for the shortage.

Estimated Resupply Dates

    • Teva has chlordiazepoxide 5 mg capsules in 100 count and 500 count bottles on intermittent back order and the company is releasing supplies as they become available. The 10 mg and 25 mg capsules are on back order and the company estimates release dates in mid-September 2021. The 10 mg capsules in 500 count bottles are available with short expiration dating (November 2021).

Updated

Updated July 15, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 20, 2019 by Rachael Freeman, PharmD, BCPS. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.